EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma

Stacie S Wang iD, Alexander J Davenport iD, Melinda Iliopoulos, Hannah E Hughes-Parry iD, Katherine A Watson iD, Valeria Arcucci iD, Matthias Mulazzani iD, David D Eisenstat iD, Jordan R Hansford iD, Ryan S Cross iD, Misty R Jenkins iD

Neuro-Oncology Advances · 01.01.2023 · 5 (1)

DOI: 10.1093/noajnl/vdad024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 04.05.2023. Verfasst von Stacie S Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Cancer Aid, National Health and Medical Research Council, Robert Connor Dawes Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMG) of the thalamus and spinal cord are rare but devastating high-grade glial tumors of childhood with no curative treatment. Despite aggressive treatment attempts the prognosis has remained poor. Chimeric antigen receptor (CAR) T cell therapy has been identified as a promising new approach in the treatment of DMG tumors; however, additional targets are urgently required given known tumor heterogeneity and the prospect of antigen escape of this cancer.

Methods

Using cell surface mass spectrometry, we detected high HER2 cell surface protein across a panel of patient-derived DIPG cells, thereby identifying an existing CAR T cell therapy for use in DIPG. Primary human T cells were transduced to express a second-generation HER2 CAR and interrogated for efficacy against patient-derived DIPG cells.

Results

HER2 CAR T cells demonstrated potent and antigen-specific cytotoxicity and cytokine secretion when co-cultured with patient-derived DIPG cells. Furthermore, HER2 CAR T cells provided a significant regression in intracranial DIPG xenograft tumors.

Conclusions

HER2 CAR T cells are already in clinic development and are well tolerated in pediatric patients. Here we provide strong preclinical evidence for the inclusion of DIPG patients in future pediatric CNS tumor HER2 CAR T cell clinical trials.

Schlagwörter

Stichwörter der Autor:innen

Chimeric antigen receptor (CAR) T cellsdiffuse intrinsic pontine glioma (DIPG)diffuse midline glioma (DMG)human epidermal growth factor receptor 2 (HER2)immunotherapy

Autor:innen und Institutionen

  • Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • Murdoch Children's Research Institute, Parkville, VIC, Australia.
  • Children's Cancer Centre, Royal Children's Hospital, Parkville, VIC, Australia.
  • Michael Rice Cancer Centre, Women's and Children's Hospital, South Australia Health and Medical Research Institute, South Australia ImmunoGENomics Cancer Institute, University of Adelaide, Adelaide, South Australia, Aus…
  • Department of Medical Biology, University of Melbourne, Parkville, Australia.
  • Department of Biochemistry, La Trobe Institute for Molecular Science, Bundoora, VICAustralia.

ORCID-Profile: Stacie S Wang, Alexander J Davenport, Hannah E Hughes-Parry, Katherine A Watson, Valeria Arcucci, Matthias Mulazzani, David D Eisenstat, Jordan R Hansford, Ryan S Cross, Misty R Jenkins

Förderung

  • German Cancer Aid
  • National Health and Medical Research Council
  • Robert Connor Dawes Foundation
  • Isabella and Marcus Foundation
  • Victorian Paediatric Cancer Consortium
  • Cancer Australia

Zitieren

APA

Wang, S. S., Davenport, A. J., Iliopoulos, M., Hughes-Parry, H. E., Watson, K. A., Arcucci, V., Mulazzani, M., Eisenstat, D. D., Hansford, J. R., Cross, R. S., & Jenkins, M. R. (2023). HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma. Neuro-Oncology Advances, 5(1). https://doi.org/10.1093/noajnl/vdad024

Vancouver

Wang SS, Davenport AJ, Iliopoulos M, Hughes-Parry HE, Watson KA, Arcucci V, et al. HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma. Neuro-Oncology Advances. 2023;5(1). doi:10.1093/noajnl/vdad024

BibTeX
@article{Wang2023,
  author = {Wang, Stacie S and Davenport, Alexander J and Iliopoulos, Melinda and Hughes-Parry, Hannah E and Watson, Katherine A and Arcucci, Valeria and Mulazzani, Matthias and Eisenstat, David D and Hansford, Jordan R and Cross, Ryan S and Jenkins, Misty R},
  title = {HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma},
  journal = {Neuro-Oncology Advances},
  year = {2023},
  volume = {5},
  number = {1},
  doi = {10.1093/noajnl/vdad024}
}
Kostenlos starten →